slides · global inventory
All filtered slides
Global slide inventory for the active corpus filters, with each row opening the slide detail view.
Corpus coverage
319,975 slides
319,974 are described (100%), so the treemap can explain the corpus instead of just counting files.
- Total slides
- 319,975
- Described
- 319,974
- Pending
- 1
100%ready for canon
Slide type composition
dynamicclickable
Slide type
Showing 319,974 described slides — 100.0% of 319,975 rendered pages
+Context & problem43,76713.7% · 6,592 docs+Data & charts72,62022.7% · 8,666 docs+Meta & navigation45,93614.4% · 9,739 docs+Recommend & act67,04121.0% · 9,324 docs+Cases & evidence31,2569.8% · 6,067 docs+Frameworks2,1230.7% · 1,232 docs+Appendix35,68211.2% · 6,614 docs+Other21,5496.7% · 5,566 docs
Tile area is proportional to slide count. Click a category to open its subtype map.
all document kinds · all orientations
Slide collection
230,191-230,220 of 319,975
44
The slide uses a small multiples approach to show individual patient responses, then aggregates them into two groups (I and II) to demonstrate differential sensitivity.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
45
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
46
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
47
The slide uses a molecular visualization as a background element to represent the drug target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
48
The slide outlines a standard oncology clinical trial design (Phase 1/2) with a transition point at RP2D (Recommended Phase 2 Dose).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
49
The slide uses a human anatomy diagram to map specific cancer types to their locations, providing a visual representation of the addressable market.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
50
Includes a biological pathway diagram and a list of potential cancer indications.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
51
The slide uses a three-column layout to define the target product profile (TPP) for a CDK7 inhibitor.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
52
The slide uses a color-coded heatmap to visualize performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
53
Data source: Besnard et al, AACR (2022).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
54
The slide uses two distinct charts to correlate drug exposure time with physiological toxicity (body weight change).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
55
The chart displays sensitivity across 60+ samples. The right side shows a volcano plot for pathway analysis and a conceptual diagram for combination testing.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
56
The slide uses a waterfall plot for single-agent sensitivity and a heatmap for combination synergy, highlighting specific patient response rates for different mechanisms of action.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
57
Includes a Venn diagram and two line charts showing Log2FoldChange vs concentration.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
58
The slide features a 3D molecular visualization of the protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
59
The chart compares % Reduction PLN Weight across different doses of EXS4318 versus a failed competitor drug.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
60
The slide uses a traffic-light color coding system to highlight the superior profile of EXS4318.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
61
The slide uses a process-flow layout with icons representing each stage.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
62
The background features a 3D molecular visualization, likely representing the LSD1 protein target.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
63
The slide uses a human anatomy diagram to map specific patient counts to disease locations.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
64
The slide uses a hub-and-spoke diagram to illustrate the interaction of LSD1 with various protein complexes, receptors, and RNAs.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
65
The slide uses a biological process diagram to explain the mechanism of action for a drug candidate ('539).Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
66
The slide uses a process flow diagram to explain the therapeutic mechanism.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
67
Exscientia | Investor Presentation Deck | 93 slidesExscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
68
The slide uses a three-column layout to define the technical requirements for a drug candidate.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
69
The table uses a traffic-light color coding system to indicate performance against criteria.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
70
The slide outlines a specific workflow involving generative design, ML, and active learning.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
71
The chart uses a scatter plot to visualize the Pareto front in drug discovery, highlighting the selection of compounds 1 and 2.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
72
The slide uses two distinct chart types (dot plot and line chart with error bars) to illustrate the safety profile of the drug candidate '539.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit
73
Data shows heterogeneity of response across different patient samples, categorized by differentiation level.Exscientia | Investor Presentation Deck | 93 slides · Exscientia
Pitch deck Investor relations Beat · Traction1 hit